T HYROID CARCINOMA IS the most frequent malignant endocrine tumor in humans. Thyroid neoplasia includes tumors with different molecular and clinical features including differentiated follicular and papillary carcinomas, poorly differentiated papillary and follicular carcinomas and undifferentiated anaplastic carcinomas (1, 2) . Papillary carcinomas represent more than 70% of thyroid malignant tumors and rearrangements of RET gene have represented for years the most frequent genetic alterations found in papillary carcinomas (3, 4) . More recently several studies (5-9) indicated a high percentage of B-RAF mutations in thyroid papillary carcinomas. Follicular carcinomas are differentiated thyroid tumors, which frequently show RAS genes activating mutations (10) and paired domain-containing transcription factor (PAX-8) and peroxisome proliferator-activated receptor (PPAR) gamma 1 rearrangements (11) . Poorly differentiated and anaplastic carcinomas derive from differentiated carcinomas through a process of neoplastic progression. Alterations of the p53 tumor suppressor gene are a peculiar feature of anaplastic carcinomas (12) (13) (14) . Although critical molecular mechanisms of thyroid tumorigenesis have been identified, other molecular steps of thyroid neoplastic progression need to be clarified. Unstable chromosome number in cancer cells is currently believed to act as a driving force during the malignant progression, and aneuploidy is the most prevalent genomic alteration identified in solid tumors (15, 16) . Alterations in chromosome number are common in follicular thyroid carcinomas (17, 18) ; however, the cause of aneuploidy in many sporadic thyroid cancers is currently unknown.
A critical step for the maintenance of genetic stability is the chromosome segregation, which requires a high coordination of cellular process (19, 20) . Loss of the mitotic regulation is a possible cause of aneuploidy in human epithelial malignancy, and it is thought to create an abnormal nuclear morphology in cancer cells. The serine/theronine protein kinases of the Aurora family genes play a regulatory role from G 2 to cytokinesis, encompassing key cell cycle events such as centrosome duplication, chromosome biorientation, and segregation (21, 22) . The family of the Aurora genes includes Aurora A/STK-15, Aurora B/AIM-1, and AURORA C/AIK3. Aurora A is overexpressed in several solid tumors, and NIH 3T3 fibroblasts overexpressing Aurora A gene show an increase in centrosome number and aneuploidy, leading to neoplastic transformation (23, 24) . A polymorphism in Aurora A gene has been also associated with a certain degree of aneuploidy in human tumors (25) .
Aurora B (AIM1) is a chromosome passenger protein, localizing on centromeres from prophase through the met-aphase-anaphase transition (21, 26 -30) . Another chromosome passenger protein is INCENP, which tightly associates with Aurora B, probably regulating its activity. Survivin, a conserved inhibitor of apoptosis-like protein, is a third member of the Aurora B complex (19, 20) . Aurora B has been described to phosphorylate histone H3 at ser-10, and phosphorylation of histone H3 is required for proper chromosome dynamics during mitosis (26 -30) . It has also been demonstrated that Aurora B overexpression in diploid human cells normal human diploid fibroblast induces multinuclearity. Furthermore, Aurora B-transfected cells have an unstable chromosome number and show an aggressive phenotype in vivo (29, 30) .
Because Aurora B plays a crucial role for chromosome dynamics and aneuploidy is a common feature of thyroid carcinomas, we analyzed Aurora B expression in human thyroid carcinoma cell lines, originating from different histotypes and archive thyroid carcinoma tissue. All of the thyroid carcinoma cell lines showed increased Aurora B levels. Immunohistochemical studies performed on archive samples showed a clear expression of Aurora B in thyroid carcinomas, with a strong signal in anaplastic thyroid carcinomas, whereas Aurora B was not detectable in normal thyroid tissue. The block of Aurora B synthesis by RNA interference (RNAi) induced growth inhibition in human thyroid anaplastic carcinoma cells. The same effect was achieved treating anaplastic thyroid carcinoma cells with an inhibitor of the Aurora kinases.
Materials and Methods

Cell lines, plasmids, and transfections
The human anaplastic thyroid carcinoma cell lines used in the study are ARO, FRO, 8550-C, BHT 101, KAT-18, Cal 62, and KAT-4.
ARO and FRO human thyroid anaplastic carcinoma cell lines were obtained by Dr. G. The NPA line derived from poorly differentiated papillary carcinoma and was obtained by Dr. Juillard, the TPC 1 cell line derived from a papillary thyroid carcinoma (31) , and the WRO and FB1 cell lines derived from a follicular carcinoma (32, 33) .
Cells were grown in DMEM medium supplemented with 10% fetal calf serum and ampicillin/streptomycin.
Cell proliferation was evaluated by using a colorimetric assay for determining the number of viable cells, Cell Titer 96 Aqueous cell proliferation assay (Promega, Madison, WI) according to the manufacturer's suggestions.
The pCMV-AIM1 construct, containing the human Aurora B gene cDNA (accession no. NM 004217), was obtained as follows: mRNA from human testis (Clontech, Palo Alto, CA) was reverse transcribed using random hexamers as primers and Muloney leukemia virus reverse transcriptase (Applied Biosystems, Foster City, CA) to yield cDNA. The forward (5Ј-CTCTGGATCCATGGCCCAGAAGGAGAAC-3Ј) and reverse (5Ј-ACAGGGATCCTCAGGCGACAGATTGAAG-3Ј) primers were used to amplify the cDNA. The PCR product was cloned into the BamH1 site of the pcDNA His-tagged (Invitrogen Life Technologies, Carlsbad, CA).
The pCMV AIM-1 sense and antisense constructs were obtained by inserting the Aurora B cDNA in both sense and antisense orientation in the pCMV vector under the transcriptional control of the cytomegalovirus promoter. The vector also carries the gene for G418 resistance. The transfection was performed according to the calcium phosphate transfection protocol (32) . After 36 h the cells were trypsinized and expanded, and stable transfectants were generated after selection with 400 g/ml geneticin (G418) (Life Technologies, Italy). Six independent clones were isolated from pCMV AIM-1 sense, pCMV AIM-1 antisense, and control transfections. The clones carrying sense or antisense plasmid were then selected for further experiments.
The quinazoline derivative: N- [4-(6,7- dimethoxy-quinazolin-4-ylamino)-phenyl]-benzamide (34) was dissolved in dimethylsulfoxide at a concentration of 10 mm. Then 1 ϫ 10 3 ARO cells were plated in a 96-well plate, and after 24 h the cells were treated with 5, 10, or 15 m of the inhibitor. Cell proliferation was evaluated after 24 and 48 h by using the Cell Titer 96 aqueous cell proliferation assay (Promega). Soft agar colony assays were performed according to a previously described technique (35) .
Synthesis of Aurora kinase inhibitor
For the synthesis of Aurora kinase inhibitor, the methodology described elsewhere (34) was followed.
RNAi and transfection of RNA oligonucleotides
For design of small interfering RNA (siRNA) oligos targeting Aurora B, the sequence AAG GAGAACUCCUACCCCUGG (RNAi) was selected, corresponding to the nucleotides located 67-87 bp of the human Aurora B gene. As a control of siRNA oligo, the following aspecific sequence was used AAG GUC CCC AUC CUC AAG AGG (RNAc). The siRNAs were purchased from Dharmacon Research (Lafayette, CO).
Approximately 6 ϫ 10 5 cells were plated per 6-well plate in media containing 10% fetal bovine serum to give 30 -50% confluence. Transfection of the RNA oligonucleotides was performed after 24 h to result in a final RNA concentration of 200 nm. Transfections were performed using Oligofectamine (Invitrogen, Carlsbad, CA).
Human thyroid tissue samples, semiquantitative RT-PCR, real-time PCR, and immunohistochemistry
Normal and neoplastic human thyroid tissue was obtained from surgical specimens and immediately frozen in liquid nitrogen. Thyroid tumors were collected at the Laboratoire d'Histologie et de Cytologie, Centre Hospitalier Lyon Sud, France, and the Laboratoire d'Anatomie Pathologique, Hospital de L'Antiquaille Lyon, France. Total RNA was isolated and DNase digested using the RNeasy minikit (Qiagen, Valencia, CA) according to the manufacturer's recommendations. Three micrograms of total RNA from each sample were reverse transcribed using random hexamers as primers and Moloney leukemia virus reverse transcriptase (Applied Biosystems) to yield cDNA. Semiquantitative RT-PCR was carried out on cDNA using the GeneAmp PCR System 9600 (Applied Biosystems). A RNA PCR core kit (Applied Biosystems) was used to perform PCR. The human ␤-actin gene primers, amplifying a 109-bp cDNA fragment, were used as a control with the following program: 95 C for 10 min; 25 cycles at 95 C for 30 sec, 60 C for 30 sec, and 72 C for 30 sec; and 72 C for 5 min for a final extension.
To amplify the Aurora B mRNA, RT-PCR was performed using two primers that amplified a 128-bp nucleotide cDNA fragment encompassing exons 5 and 6 with the following program: 95 C for 10 min; 29 cycles of 95 C for 30 sec, 59.5 C for 30 sec, and 72 C for 30 sec; and a final extension of 72 C for 5 min.
Quantitative PCR was performed in triplicate using iCycler (Bio-Rad Laboratories, Mü nchen, Germany) with SYBR Green PCR master mix (Applied Biosystems) as follows: 95 C 10 min and 40 cycles (95 C 15 sec and 60 C 1 min). Fold mRNA overexpression was calculated according to the formula 2 (RtϪEt) /2 (RnϪEn) as described previously (36), where Rt is the threshold cycle number for the reference gene (␤-actin) in the tumor, Et for the experimental gene in the tumor, Rn for the reference gene in the normal sample, and En for the experimental gene in the normal sample. Specific primers used are as follows. Aurora B forward, 5Ј-CTGGAATATGCACCACTTGGA, reverse, 5ЈCGAATGACAGTAAG-ACAGGG; and ␤-actin-forward, 5Ј-TCGTGCGTGACATTAAGGAG; ␤-actin-reverse, 5Ј-GTCAGGCAGCTCGTAGCTCT.
The cellular distribution of Aurora B protein was assessed by immunohistochemical analysis. Aurora B expression was evaluated in both nonneoplastic and neoplastic thyroid tissues. Hematoxylin and eosinstained slides were retrieved from the files of the Department of BioMorphological Sciences at the University Federico II of Naples; in all cases the histological diagnosis was confirmed on review. Paraffinembedded sections were obtained from these samples, and Aurora B expression was evaluated. Xylene-dewaxed and alcohol-rehydrated paraffin sections were placed in Coplin jars filled with a 0.01 m trisodium citrate solution and heated for 3 min in a conventional pressure cooker. After heating, slides were thoroughly rinsed in cool running water for 5 min and then washed in Tris-buffered saline (pH 7.4).
Aurora B protein was detected by using the polyclonal antibody raised in rabbit (no. 611082; BD Transduction Laboratories, San Diego, CA). The incubation with the primary antibody was followed by incubation with biotinylated antimouse immunoglobulins and by peroxidase-labeled streptavidin (LSAB-Dako, Carpinteria, CA). The signal was developed by using diaminobenzidine chromogen as substrate. Negative controls were run with normal rabbit serum instead of the primary antibody, or the antibody was preadsorbed with the cognate peptide (10 Ϫ6 m). Cases were scored by assessing the percentage of labeled cells, and percentage of positive cells was evaluated by analyzing 1000 neoplastic cells in five different high power fields. The study was approved by the Ethics Committee of the Centre Hospitalier Lyon Sud and the University Federico II Napoli. In all cases written informed consent was obtained.
Protein extraction and Western blot analysis
Cells were homogenized directly into lysis buffer (50 mm HEPES, 150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 10% glycerol, 1%Triton X-100, 1 mm phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, 0.5 mm sodium orthovanadate, and 20 mm sodium pyrophosphate). The lysates were clarified by centrifugation at 14,000 ϫ 10 min. Protein concentrations were estimated by an assay (Bio-Rad) and boiled in Laemmli buffer [0.125 m Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, and 0.002% bromophenol blue] for 5 min before electrophoresis. Proteins were subjected to SDS-PAGE (10% polyacrylamide) under reducing conditions. After electrophoresis, proteins were transferred to nitrocellulose membranes (Immobilon, Millipore Corp., Bedford, MA); complete transfer was assessed using prestained protein standards (BioRad, Hercules, CA). After blocking with Tris-buffered saline-BSA [25 mm Tris (pH7.4), 200 mm NaCl, and 5% BSA], the membrane was incubated with the primary antibody against Aurora B for 1 h (at room temperature). Membranes were then incubated with the horseradish peroxidase-conjugated secondary antibody (1:10,000) for 45 min (at room temperature), and the reaction was detected with an enhanced chemiluminescence system (Amersham Life Science, Buckinghamshire, UK).
Tumorigenicity assay
Experiments were performed in 6-wk-old male athymic mice (Charles River, Italy). Untransfected ARO cells (1 ϫ 10 6 ) or respectively transfected with a plasmid-containing Aurora B in the sense or antisense orientation were injected into the right flank of the mice. The animals were monitored for the appearance of tumors and tumor latency evaluated. The mean tumor latency is the time needed for tumors to reach 10 mm in diameter. All mice were maintained at the Dipartimento di Biologia e Patologia Animal Facility. Animal experimentations described in the present paper have been conducted in accordance with accepted standards of animal care, in accordance with the Italian regulations for the welfare of animals used in studies of experimental neoplasia, and the study was approved by Ethics Committee on Animal Care of the University Federico II Napoli.
Results
Aurora B expression in thyroid carcinoma cell lines
Thyroid carcinoma cell lines derived from papillary carcinomas, follicular carcinomas, and anaplastic thyroid carcinomas were analyzed for Aurora B expression by Western blot. An Aurora B-specific band of 41 kDa was detected in all the samples. As shown in Fig. 1, A and B , the highest expression levels were observed in the cell lines derived from anaplastic thyroid carcinoma (ARO, FRO, 8505-C, BHT101, KAT-18, Cal 62, and KAT-4), whereas only a faint band of 41 kDa was observed in human thyroid primary culture cells.
Therefore, these data would indicate that the expression of Aurora B is more abundant in cell lines characterized by a malignant and aggressive phenotype.
Aurora B expression in experimental models of thyroid carcinogenesis
To confirm that Aurora B gene expression is increased in highly malignant thyroid carcinomas, Aurora B expression in thyroid glands obtained from animal models of thyroid carcinogenesis was evaluated by Western blot. We used transgenic animals lines expressing RET/PTC3, HPV 16 E7, and LT SV40 oncogenes under the transcriptional control of the thyroglobulin promoter.
RET/PTC3 is an oncogene frequently activated in human thyroid papillary carcinomas, and it has been shown to induce thyroid papillary carcinomas when expressed in the thyroid cells of transgenic animals (37) . Transgenic mice carrying HPV 16 E7 oncogene under the transcriptional control of the thyroglobulin gene promoter develop follicular carcinomas of the thyroid (38) , whereas thyroid anaplastic carcinomas are obtained in animals with thyroid-targeted expression of LT SV40 oncogene (39) . Thyroid glands of animals treated with the goitrogenic agent propylthiouracil (PTU) for 2 wk and 1 month (40) were used as a control for nonneoplastic proliferation. Furthermore, the thyroid gland of a 6-month-old wild-type mouse was used as a control (Fig.  1C) . The results shown are representative of three different experiments.
Elevated levels of Aurora B protein expression were observed in the experimental thyroid anaplastic carcinomas. A weaker signal was observed in the papillary and follicular carcinomas. Conversely, very low levels of Aurora B were observed in normal thyroid tissue as in thyroid glands stimulated by PTU.
Aurora B expression in the normal human thyroid and thyroid neoplastic lesions
To evaluate the expression of Aurora B in human thyroid carcinoma tissues, a panel of matched tumor/normal tissues was analyzed by RT-PCR. No significant differences in Aurora B gene expression were observed in papillary carcinomas matched with normal thyroid tissue ( Fig. 2A) , whereas an increased Aurora B expression was observed in anaplastic thyroid carcinomas with respect to the normal thyroid tissue (Fig. 2B) .
Quantitative PCR was performed to confirm overexpression of Aurora B in anaplastic thyroid carcinomas. About 15-fold mRNA overexpression was observed in ATC samples with respect to the ␤-actin reference gene. A 2-fold increase was observed in papillary thyroid carcinoma samples (Fig. 2C) .
Archive thyroid tumors comprising adenoma (five cases), follicular (five cases), papillary (10 cases), and anaplastic thyroid carcinomas (15 cases) were stained for Aurora B. As a control three cases of nodular goitre and three cases of Hashimoto's thyroiditis were analyzed. In normal thyroid tissue, few positive cells for Aurora B staining were observed. Conversely, all of thyroid anaplastic carcinoma examined showed a very high expression of Aurora B (Fig. 3,  C and D) . Positive cells were irregularly distributed throughout the tumor. Occasionally, a heterogeneous pattern of expression was seen, with areas showing strong labeling adjacent to areas with less intense Aurora B expression. The signal was most intense in dividing cells, with mitotic figures depicted by the antibody.
In follicular or papillary differentiated carcinomas, a less intense signal was observed. Also in differentiated carcinomas, signal was most intense in dividing cells, and the cytoplasm of positive cells was devoid of signal (Fig. 3B) . The expression of Aurora B in anaplastic thyroid carcinomas or differentiated carcinomas was compared with the expression of a well-known proliferative marker such as Ki-67, by using MIB-1 antibody (Table 1) . Staining for Ki-67 was most intense in thyroid anaplastic carcinomas, showing a correlation with Aurora B expression.
Effects of the suppression of the Aurora B protein synthesis in anaplastic thyroid carcinoma cells
To establish whether Aurora B expression is crucial for thyroid neoplastic cell growth and assess whether Aurora B could represent a target for antineoplastic therapy, we performed an RNAi selective gene silencing analysis using siRNAs (41) (42) (43) . We observed that Aurora B RNAi significantly decreased the synthesis of Aurora B protein in ARO cells at 48 h (Fig. 4A) . The block of Aurora B protein synthesis is specific because Aurora A levels were not affected (Fig.  4A) . Aurora B has been described to phosphorylate histone H3 at Ser-10 during mitosis in vivo. To confirm the effects of RNAi, cell lysates, respectively, obtained from RNAi treated, untreated control ARO cells, and aspecific RNA treated ARO cells were immunoblotted with anti-phospho-Ser-10 H3 histone antibody and anti-H3 histone antibody. As shown in Fig. 4A , a reduced phosphorylation of the H3 histone was observed in the RNAi-transfected cells at 48 h. RNAi treatment significantly reduced cell proliferation (Fig. 4B) .
Transfection of ARO cells with an antisense construct (pCMV AIM-1 antisense) of the Aurora B DNA was also performed. Control transfections were performed using an Aurora B sense construct (pCMV AIM-1 sense) or an empty vector (pCMV). Clones were isolated from each transfection and the integration of the constructs was confirmed by Southern blot (data not shown). The reduced expression of Aurora B protein was confirmed in pCMV AIM-1 antisense clones by Western blot analysis (data not shown). The colony growth rate in semisolid medium was reduced in Aurora B antisense-expressing clones with respect to sense transfected or control cells. Although no differences in tumor incidence were observed on injection into athymic mice, tumor latency period of Aurora B antisense-expressing clones was increased (Table 2 and Fig. 5) .
A small molecule similar to the quinazoline derivative: N- [4-(6,7- 
dimethoxy-quinazolin-4-ylamino)-phenyl]-benz-
amide has been shown to inhibit the Aurora B kinase activity (33, 44) . To further evaluate the role of the Aurora B kinase activity on thyroid carcinoma cell proliferation, 5 ϫ 10 5 ARO and 5 ϫ 10 5 FRO cells were treated with 15 m of the Aurora kinase inhibitor; after 24 and 48 h, cells were collected and lysed. Lysates were immunoblotted with antiphospho-Ser-10 H3 histone antibody and antitubulin antibody. As shown in Fig. 6A , a dramatic reduction in phosphorylation of the H3 histone was observed in the treated cells. To evaluate the effects of Aurora kinase inhibitor on cell proliferation, ARO and FRO cells were treated with 5, 10, and 15 m, and cell proliferation was evaluated after 24 and 48 h. Ten and 15 m of Aurora kinase inhibitor significantly reduced cell proliferation (Fig. 6B) .
Discussion
Alterations of the mechanisms responsible for maintaining the chromosome balance are common in neoplastic cells (15, 16) . Disruption of mitotic checkpoints induces unstable chromosome number or aneuploidy, which is thought to create abnormal nuclear morphology in cancer cells and contribute to genetic instability. It has been described that alterations in chromosome number are common in neoplasias from thyroid follicular cells; however, the mutational analysis of two components of the spindle assembly checkpoint pathway, BUB1 and BURBR1, has shown that these two proteins do not account for the development of aneuploidy in thyroid cancer (17) . The Aurora protein kinases play a crucial role in the regulation of the cell cycle processes. Three Aurora-related kinases have been described in mammals, Aurora A (STK15), Aurora B (AIM 1), and Aurora C (STK13) (19 -21) . All three mammalian members of this family are overexpressed in human cancer cells. Overexpression of Aurora A is thought to relate to multiple centrosome production, and its role has been evaluated in human mammary (45) , pancreatic (46) , and other neoplastic lesions (47, 48) .
A significant overexpression of Aurora B has been observed in human cancer cell lines and colorectal tumors, and a correlation between Aurora B expression levels and Duke's grade in colorectal tumors has been described (30, 49) . Furthermore, it has been observed that the forced expression of Aurora B produced aneuploid cells with a malignant and aggressive phenotype, indicating that Aurora B is relevant in aneuploidy development during carcinogenesis (29) . Recently it has been shown that high expression levels of Aurora B are a consistent feature of human seminomas (50) .
In the present study, we evaluated the expression of Aurora B in thyroid carcinoma cell lines and experimental and human thyroid tumors, and we observed that the expression of Aurora B is increased in cell lines derived from thyroid anaplastic carcinomas. An increase of Aurora B expression was observed in experimental anaplastic thyroid tumors, whereas in differentiated experimental thyroid tumors, a lower expression of the Aurora B gene was observed. It is important to note that a very low expression of Aurora B was observed in the glands of animals treated with PTU, despite the intense mitotic activity of the follicular cells (40) . These data indicate that Aurora B-increased expression is associated with the late stages of thyroid tumor progression and suggest that the Aurora B overexpression could contribute to thyroid tumor progression.
The immunohistochemical analysis of neoplastic or nonneoplastic thyroid lesions paralleled the results obtained using cell lines and experimental tumors, showing that the expression is abundant in anaplastic carcinomas. Conversely, no or low expression was observed in benign adenomas, nonneoplastic thyroid lesions such as Hashimoto disease, and normal thyroid tissue. Our data on thyroid carcinomas extend to this type of tumor the observation that the expression of Aurora B displays a tendency to group in higher grade of malignancy as previously observed in colon carcinomas (49) . This observation suggests that during tumor progression, in particular during the transition from differentiated thyroid carcinomas to anaplastic thyroid carcinomas, Aurora B overexpression takes place, and Aurora B overexpression might confer a growth advantage to the neoplastic cells. Furthermore, our data indicate that Aurora B expression may serve as a prognostic marker in thyroid tumors. a Colonies larger than 64 cells were scored after 3 wk. Colonyforming efficiency was calculated with the formula: number of colonies formed/number of plated cells ϫ 100.
b Tumorigenicity was assayed by injecting 1 ϫ 10 6 cells into athymic mice (6 wk old).
c The animals were monitored for the appearance of tumors. The mean tumor latency is the time needed for tumors to reach 10 mm in diameter. In pCMV Aurora B antisense transfected cells, the median tumor latency differed significantly from that of control.
In our study, the functional consequences of RNAi-mediated decrease of Aurora B expression in anaplastic thyroid cancer cells were determined using assays of gene expression and cellular proliferation. Our results demonstrate that the Aurora B siRNA treatment induces a significant reduction in cell proliferation. No cells with apoptotic figures were observed, and the analysis of the apoptotic cascade indicated that the pathway was not activated by the Aurora B RNAi treatment (data not shown). It is possible to conclude that the block of Aurora B protein synthesis does not induce apoptosis in ARO cell line; moreover, an accumulation of Aurora B RNAi-treated cells in G 2 /M phase was observed by flow cytometry (data not shown). The inhibition ARO cells proliferation was about 40% on RNAi treatment; these data indicate that cell proliferation is not completely dependent on Aurora B activity.
Aurora B cDNA antisense transfection decreased colony formation in soft agar and resulted in increased tumor latency. By using a selective Aurora B kinase inhibitor, we confirmed that the block of Aurora B activity dramatically reduces the proliferation of anaplastic thyroid carcinoma cells.
Anaplastic thyroid carcinoma is resistant to currently available therapeutic agents. The observation that the block of Aurora B expression or activity reduces the proliferation of anaplastic thyroid carcinoma cells could contribute to the development of novel therapeutic strategies.
In conclusion, our data indicate that in thyroid carcinomas Aurora B gene expression levels are correlated to the stage of malignant progression, and the block of Aurora B expression or its kinase activity significantly reduces the growth of thyroid anaplastic carcinoma cells, suggesting that Aurora B is a potential therapeutic target. 
